In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Health Equity and Access under the 
Law for Immigrant Women and Families Act of 2014'' or as the ``HEAL 
Immigrant Women and Families Act of 2014''.

SEC. 2. FINDINGS.

    Congress finds as follows:
            (1) Insurance coverage reduces harmful health disparities 
        by alleviating cost barriers to and increasing utilization of 
        basic preventive health services, especially among low-income 
        and underserved populations, and especially among women.
            (2) Based solely on their immigration status, many 
        immigrants and their families face legal restrictions on their 
        ability to obtain health insurance coverage through Medicaid, 
        CHIP, and Health Insurance Exchanges.
            (3) Lack of health insurance contributes to persistent 
        disparities in the prevention, diagnosis, and treatment of 
        negative health outcomes borne by immigrants and their 
        families.
            (4) Immigrant women are disproportionately of reproductive 
        age, low-income, and lacking health insurance coverage. Legal 
        barriers to affordable health insurance coverage therefore 
        particularly exacerbate their risk of negative sexual, 
        reproductive, and maternal health outcomes, with lasting health 
        and economic consequences for immigrant women, their families, 
        and society as a whole.
            (5) Denying coverage or imposing waiting periods for 
        coverage unfairly hinders the ability of immigrants to take 
        responsibility for their own health and economic well-being and 
        that of their families. To fully and productively participate 
        in society, access to health care is fundamental, which for 
        women includes access to the services necessary to plan whether 
        and when to have a child.
            (6) The population of immigrant families in the United 
        States is expected to continue to grow. Indeed one in five 
        children in the United States is part of an immigrant family. 
        It is therefore in the nation's shared public health and 
        economic interest to remove legal barriers to affordable health 
        insurance coverage based on immigration status.

SEC. 3. REMOVING BARRIERS TO HEALTH COVERAGE FOR LAWFULLY PRESENT 
              INDIVIDUALS.

    (a) Medicaid.--Section 1903(v)(4) of the Social Security Act (42 
U.S.C. 1396b(v)(4)) is amended--
            (1) by amending subparagraph (A) to read as follows:
    ``(A) Notwithstanding sections 401(a), 402(b), 403, and 421 of the 
Personal Responsibility and Work Opportunity Reconciliation Act of 
1996, payment shall be made under this section for care and services 
that are furnished to aliens, including those described in paragraph 
(1), if they otherwise meet the eligibility requirements for medical 
assistance under the State plan approved under this title (other than 
the requirement of the receipt of aid or assistance under title IV, 
supplemental security income benefits under title XVI, or a State 
supplementary payment), and are lawfully present in the United 
States.'';
            (2) in subparagraph (B)--
                    (A) by striking ``a State that has elected to 
                provide medical assistance to a category of aliens 
                under subparagraph (A)'' and inserting ``aliens 
                provided medical assistance pursuant to subparagraph 
                (A)''; and
                    (B) by striking ``to such category'' and inserting 
                ``to such alien''; and
            (3) in subparagraph (C)--
                    (A) by striking ``an election by the State under 
                subparagraph (A)'' and inserting ``the application of 
                subparagraph (A)'';
                    (B) by inserting ``or be lawfully present'' after 
                ``lawfully reside''; and
                    (C) by inserting ``or present'' after ``lawfully 
                residing'' each place it appears.
    (b) CHIP.--Subparagraph (J) of section 2107(e)(1) of the Social 
Security Act (42 U.S.C. 1397gg(e)(1)) is amended to read as follows:
                    ``(J) Paragraph (4) of section 1903(v) (relating to 
                lawfully present individuals).''.
    (c) Effective Date.--
            (1) In general.--Except as provided in paragraph (2), the 
        amendments made by this section shall take effect on the date 
        of the enactment of this Act and shall apply to services 
        furnished on or after the date that is 90 days after such date 
        of the enactment.
            (2) Exception if state legislation required.--In the case 
        of a State plan for medical assistance under title XIX, or a 
        State child health plan under title XXI, of the Social Security 
        Act which the Secretary of Health and Human Services determines 
        requires State legislation (other than legislation 
        appropriating funds) in order for the plan to meet the 
        additional requirements imposed by the amendments made by this 
        section, the respective State plan shall not be regarded as 
        failing to comply with the requirements of such title solely on 
        the basis of its failure to meet these additional requirements 
        before the first day of the first calendar quarter beginning 
        after the close of the first regular session of the State 
        legislature that begins after the date of the enactment of this 
        Act. For purposes of the previous sentence, in the case of a 
        State that has a 2-year legislative session, each year of such 
        session shall be deemed to be a separate regular session of the 
        State legislature.

SEC. 4. REMOVING BARRIERS TO HEALTH COVERAGE FOR INDIVIDUALS GRANTED 
              DEFERRED ACTION FOR CHILDHOOD ARRIVALS.

    (a) In General.--For the purposes of eligibility under any of the 
provisions referred to in subsection (b), individuals granted deferred 
action under the Deferred Action for Childhood Arrivals process of the 
Department of Homeland Security, as described in the memorandum of the 
Secretary of Homeland Security on June 15, 2012, shall be considered 
lawfully present in the United States.
    (b) Provisions Described.--The provisions described in this 
subsection are the following:
            (1) Exchange eligibility.--Section 1311 of the Patient 
        Protection and Affordable Care Act (42 U.S.C. 18031).
            (2) Reduced cost-sharing eligibility.--Section 1402 of the 
        Patient Protection and Affordable Care Act (42 U.S.C. 18071).
            (3) Premium subsidy eligibility.--Section 36B of the 
        Internal Revenue Code of 1986.
            (4) Medicaid and chip eligibility.--Titles XIX and XXI of 
        the Social Security Act, including under section 1903(v) of 
        such Act (42 U.S.C. 1396b(v)).
    (c) Effective Date.--
            (1) In general.--Subsection (a) shall take effect on the 
        date of the enactment of this Act.
            (2) Transition through special enrollment period.--In the 
        case of an individual described in subsection (a) who, before 
        the first day of the first annual open enrollment period under 
        subparagraph (B) of section 1311(c)(6) of the Patient 
        Protection and Affordable Care Act (42 U.S.C. 18031(c)(6)) 
        beginning after the date of the enactment of this Act, is 
        granted deferred action described in subsection (a) and who, as 
        a result of such subsection, qualifies for a subsidy described 
        in paragraph (2) or (3) of such subsection, the Secretary of 
        Health and Human Services shall establish a special enrollment 
        period under section 1311(c)(6)(C) of such Act during which 
        such individual may enroll in qualified health plans through 
        Exchanges under title I of such Act and qualify for such a 
        subsidy. For such an individual who has been granted deferred 
        action as of the date of the enactment of this Act, such 
        special enrollment period shall begin not later than 90 days 
        after such date of enactment. Nothing in this paragraph shall 
        be construed as affecting the authority of the Secretary to 
        establish additional special enrollment periods under section 
        1311(c)(6)(C) of the Patient Protection and Affordable Care Act 
        (42 U.S.C. 18031(c)(6)(C)).

A: Health Equity and Access under the Law for Immigrant Women and Families Act of 2014 or the HEAL Immigrant Women and Families Act of 2014 - Amends titles XIX (Medicaid) and XXI (Children's Health Insurance) (CHIP) of the Social Security Act to extend Medicaid and CHIP coverage to aliens lawfully present in the United States.  Makes individuals granted deferred action under the Deferred Action for Childhood Arrivals process eligible for: (1) health care exchanges and reduced cost sharing under the Patient Protection and Affordable Care Act, (2) premium subsidies under the Internal Revenue Code, and (3) Medicaid and CHIP.
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``United States-Israel Cybersecurity 
Cooperation Enhancement Act of 2016''.

SEC. 2. UNITED STATES-ISRAEL CYBERSECURITY COOPERATION.

    (a) Grant Program.--
            (1) Establishment.--The Secretary, in accordance with the 
        agreement entitled the ``Agreement between the Government of 
        the United States of America and the Government of the State of 
        Israel on Cooperation in Science and Technology for Homeland 
        Security Matters'', dated May 29, 2008 (or successor 
        agreement), and the requirements specified in paragraph (2), 
        shall establish a grant program at the Department to support--
                    (A) cybersecurity research and development; and
                    (B) demonstration and commercialization of 
                cybersecurity technology.
            (2) Requirements.--
                    (A) Applicability.--Notwithstanding any other 
                provision of law, in carrying out a research, 
                development, demonstration, or commercial application 
                program or activity that is authorized under this 
                section, the Secretary shall require cost sharing in 
                accordance with this paragraph.
                    (B) Research and development.--
                            (i) In general.--Except as provided in 
                        clause (ii), the Secretary shall require not 
                        less than 50 percent of the cost of a research, 
                        development, demonstration, or commercial 
                        application program or activity described in 
                        subparagraph (A) to be provided by a non-
                        Federal source.
                            (ii) Reduction.--The Secretary may reduce 
                        or eliminate, on a case-by-case basis, the 
                        percentage requirement specified in clause (i) 
                        if the Secretary determines that such reduction 
                        or elimination is necessary and appropriate.
                    (C) Merit review.--In carrying out a research, 
                development, demonstration, or commercial application 
                program or activity that is authorized under this 
                section, awards shall be made only after an impartial 
                review of the scientific and technical merit of the 
                proposals for such awards has been carried out by or 
                for the Department.
                    (D) Review processes.--In carrying out a review 
                under subparagraph (C), the Secretary may use merit 
                review processes developed under section 302(14) of the 
                Homeland Security Act of 2002 (6 U.S.C. 182(14)).
            (3) Eligible applicants.--An applicant shall be eligible to 
        receive a grant under this subsection if the project of such 
        applicant--
                    (A) addresses a requirement in the area of 
                cybersecurity research or cybersecurity technology, as 
                determined by the Secretary; and
                    (B) is a joint venture between--
                            (i)(I) a for-profit business entity, 
                        academic institution, National Laboratory (as 
                        defined in section 2 of the Energy Policy Act 
                        of 2005 (42 U.S.C. 15801)), or nonprofit entity 
                        in the United States; and
                            (II) a for-profit business entity, academic 
                        institution, or nonprofit entity in Israel; or
                            (ii)(I) the Federal Government; and
                            (II) the Government of Israel.
            (4) Applications.--To be eligible to receive a grant under 
        this subsection, an applicant shall submit to the Secretary an 
        application for such grant in accordance with procedures 
        established by the Secretary, in consultation with the advisory 
        board established under paragraph (5).
            (5) Advisory board.--
                    (A) Establishment.--The Secretary shall establish 
                an advisory board to--
                            (i) monitor the method by which grants are 
                        awarded under this subsection; and
                            (ii) provide to the Secretary periodic 
                        performance reviews of actions taken to carry 
                        out this subsection.
                    (B) Composition.--The advisory board established 
                under subparagraph (A) shall be composed of three 
                members, to be appointed by the Secretary, of whom--
                            (i) one shall be a representative of the 
                        Federal Government;
                            (ii) one shall be selected from a list of 
                        nominees provided by the United States-Israel 
                        Binational Science Foundation; and
                            (iii) one shall be selected from a list of 
                        nominees provided by the United States-Israel 
                        Binational Industrial Research and Development 
                        Foundation.
            (6) Contributed funds.--Notwithstanding any other provision 
        of law, the Secretary may accept or retain funds contributed by 
        any person, government entity, or organization for purposes of 
        carrying out this subsection. Such funds shall be available, 
        subject to appropriation, without fiscal year limitation.
            (7) Report.--Not later than 180 days after the date of 
        completion of a project for which a grant is provided under 
        this subsection, the grant recipient shall submit to the 
        Secretary a report that contains--
                    (A) a description of how the grant funds were used 
                by the recipient; and
                    (B) an evaluation of the level of success of each 
                project funded by the grant.
            (8) Classification.--Grants shall be awarded under this 
        subsection only for projects that are considered to be 
        unclassified by both the United States and Israel.
    (b) Termination.--The grant program and the advisory board 
established under this section terminate on the date that is seven 
years after the date of the enactment of this Act.
    (c) Prohibition on Additional Funding.--No additional funds are 
authorized to be appropriated to carry out this Act.
    (d) Definitions.--In this section--
            (1) the term ``cybersecurity research'' means research, 
        including social science research, into ways to identify, 
        protect against, detect, respond to, and recover from 
        cybersecurity threats;
            (2) the term ``cybersecurity technology'' means technology 
        intended to identify, protect against, detect, respond to, and 
        recover from cybersecurity threats;
            (3) the term ``cybersecurity threat'' has the meaning given 
        such term in section 102 of the Cybersecurity Information 
        Sharing Act of 2015 (enacted as title I of the Cybersecurity 
        Act of 2015 (division N of the Consolidated Appropriations Act, 
        2016 (Public Law 114-113)));
            (4) the term ``Department'' means the Department of 
        Homeland Security; and
            (5) the term ``Secretary'' means the Secretary of Homeland 
        Security.

            Passed the House of Representatives November 29, 2016.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.

A: United States-Israel Cybersecurity Cooperation Enhancement Act of 2016  (Sec. 2) This bill requires the Department of Homeland Security (DHS) to establish a grant program to support cybersecurity research and development, and the demonstration and commercialization of cybersecurity technology, in accordance with the Agreement between the Government of the United States of America and the Government of the State of Israel on Cooperation in Science and Technology for Homeland Security Matters, dated May 29, 2008, or a successor agreement.  Grants may be awarded for social science research and technology intended to identify, protect against, respond to, and recover from cybersecurity threats. To be eligible for a grant, a project must be a joint venture between: (1) for-profit, nonprofit, or academic entities (including U.S. national laboratories) in the United States and Israel; or (2) the governments of the United States and Israel.  Grants shall be awarded only for projects considered unclassified by both the United States and Israel. DHS must require cost sharing of at least 50% from nonfederal sources for grant activities, but it may reduce the nonfederal percentage if necessary on a case-by-case basis.  DHS must establish an advisory board to monitor the impartial scientific and technical merit method by which grants are awarded and provide periodic reviews of the actions taken to carry out the program. The grant program terminates seven years after this bill's enactment. 
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Fair Medicaid Drug Payment Act of 
2007''.

SEC. 2. PROVIDING ADEQUATE PHARMACY REIMBURSEMENT UNDER MEDICAID.

    (a) Pharmacy Reimbursement Limits.--
            (1) In general.--Section 1927(e) of the Social Security Act 
        (42 U.S.C. 1396r-8(e)) is amended--
                    (A) in paragraph (4), by striking ``(or, effective 
                January 1, 2007, two or more)''; and
                    (B) by striking paragraph (5) and inserting the 
                following:
            ``(5) Use of amp in upper payment limits.--The Secretary 
        shall calculate the Federal upper reimbursement limit 
        established under paragraph (4) as no less than 300 percent of 
        the weighted average (determined on the basis of utilization) 
        of the most recent average manufacturer prices for 
        pharmaceutically and therapeutically equivalent multiple source 
        drug products that are available for purchase by retail 
        community pharmacies on a nationwide basis. The Secretary shall 
        implement a smoothing process for average manufacturer prices 
        to ensure that Federal upper reimbursement limits do not vary 
        significantly from month to month as a result of rebates, 
        discounts, and other pricing practices. Such process shall be 
        similar to the smoothing process used in determining the 
        average sales price of a drug or biological under section 
        1847A.''.
            (2) Definition of amp.--Section 1927(k)(1) of such Act (42 
        U.S.C. 1396r-8(k)(1)) is amended--
                    (A) in subparagraph (A), by striking ``by'' and all 
                that follows through the period and inserting ``by--
                            ``(i) wholesalers for drugs distributed to 
                        retail community pharmacies; and
                            ``(ii) retail community pharmacies that 
                        purchase drugs directly from the 
                        manufacturer.''; and
                    (B) in subparagraph (B)--
                            (i) in the subparagraph heading, by 
                        striking ``extended to wholesalers'' and 
                        inserting ``and other payments''; and
                            (ii) by striking ``regard to'' and all that 
                        follows through the period and inserting 
                        ``regard to--
                            ``(i) customary prompt pay discounts 
                        extended to wholesalers;
                            ``(ii) bona fide service fees paid by 
                        manufacturers to wholesalers or retail 
                        community pharmacies, including (but not 
                        limited to) distribution service fees, 
                        inventory management fees, product stocking 
                        allowances, and fees associated with 
                        administrative services agreements and patient 
                        care programs (such as medication compliance 
                        programs and patient education programs);
                            ``(iii) reimbursement by manufacturers for 
                        recalled, damaged, expired, or otherwise 
                        unsalable returned goods, including (but not 
                        limited to) reimbursement for the cost of the 
                        goods and any reimbursement of costs associated 
                        with return goods handling and processing, 
                        reverse logistics, and drug destruction;
                            ``(iv) payments received from, and rebates 
                        or discounts provided to, pharmacy benefit 
                        managers, managed care organizations, health 
                        maintenance organizations, insurers, hospitals, 
                        clinics, mail order pharmacies, long term care 
                        providers, manufacturers, or any other entity 
                        that does not conduct business primarily as a 
                        wholesaler or a retail community pharmacy;
                            ``(v) any payments made by manufacturers 
                        that are associated with drugs dispensed by 
                        retail community pharmacies; and
                            ``(vi) any other discounts, rebates, 
                        payments, or other financial transactions that 
                        are not received by, paid by, or passed through 
                        to, retail community pharmacies.''.
            (3) Definition of multiple source drug.--Section 
        1927(k)(7)(A)(i) of such Act (42 U.S.C. 1396r-8(k)(7)(A)(i)) is 
        amended--
                    (A) in the matter preceding subclause (I), by 
                striking ``there at least 1 other drug product'' and 
                inserting ``there are at least 2 other drug products''; 
                and
                    (B) in subclauses (I), (II), and (III), by striking 
                ``is'' each place it appears and inserting ``are''.
            (4) Definitions of retail community pharmacy; wholesaler.--
        Section 1927(k) of such Act (42 U.S.C. 1396r-8(k)) is amended 
        by adding at the end the following new paragraphs:
            ``(10) Retail community pharmacy.--The term `retail 
        community pharmacy' means a traditional independent pharmacy, 
        traditional chain pharmacy, a supermarket pharmacy, or a mass 
        merchandiser pharmacy that is licensed as a pharmacy by a State 
        and that dispenses medications to the general public at retail 
        prices. Such term does not include a pharmacy that dispenses 
        prescription medications to patients primarily through the 
        mail, nursing home pharmacies, long-term care facility 
        pharmacies, hospital pharmacies, clinics, charitable or not-
        for-profit pharmacies, government pharmacies, or pharmacy 
        benefit managers.
            ``(11) Wholesaler.--The term `wholesaler' means a drug 
        wholesaler that is licensed as a wholesaler by a State and that 
        is engaged in wholesale distribution of prescription drugs to 
        retail community pharmacies, including (but not limited to) 
        manufacturers, repackers, own-label distributors, private-label 
        distributors, jobbers, brokers, warehouses (including 
        manufacturer's and distributor's warehouses, chain drug 
        warehouses, and wholesale drug warehouses) independent 
        wholesale drug traders, and retail pharmacies that conduct 
        wholesale distributions.''.
    (b) Requirements of Prior Authorization Programs.--Section 
1927(d)(5) of such Act (42 U.S.C. 1396r-8(d)(5)) is amended--
            (1) in the matter preceding subparagraph (A), by striking 
        ``of the drug before its dispensing for any medically accepted 
        indication (as defined in subsection (k)(6)) only if the system 
        providing for such approval'' and inserting ``by the State of 
        the use of the drug before its dispensing for any medically 
        accepted indication (as defined in subsection (k)(6)). A State 
        plan under this title shall, as a condition of coverage or 
        payment for a covered outpatient drug for which Federal 
        financial participation is available in accordance with this 
        section, subject to prior authorization all covered outpatient 
        drug products that are innovator multiple source drugs if such 
        drug products are more expensive than other biologically and 
        therapeutically equivalent drug products that are available for 
        purchase in that State by retail community pharmacies. The 
        system providing for such approval shall'';
            (2) in each of subparagraphs (A) and (B), by striking 
        ``provides'' and inserting ``provide'';
            (3) by redesignating subparagraphs (A) and (B) (as so 
        amended) as subparagraphs (C) and (D), respectively; and
            (4) by inserting before subparagraph (C) (as so 
        redesignated), the following new subparagraphs:
                    ``(A) require the prescriber to request prior 
                authorization by substantiating the medical necessity 
                of dispensing the covered outpatient drug as opposed to 
                dispensing a substitute covered outpatient drug;
                    ``(B) require that a prior authorization number 
                assigned to the approved request by the State be 
                included on the order for the covered outpatient drug 
                issued by the prescriber or relayed to the dispensing 
                pharmacist by the prescriber if the prescription is 
                orally transmitted;''.
    (c) Disclosure of Price Information to the Public.--Section 
1927(b)(3) of such Act (42 U.S.C. 1396r-8(b)(3)) is amended--
            (1) in subparagraph (A)--
                    (A) in clause (i), in the matter preceding 
                subclause (I), by inserting ``month of a'' after 
                ``each''; and
                    (B) in the last sentence, by striking ``and 
                shall,'' and all that follows through the period; and
            (2) in subparagraph (D)--
                    (A) in clause (iii), by inserting ``and'' after the 
                comma;
                    (B) in clause (iv), by striking ``, and'' and 
                inserting a period; and
                    (C) by striking clause (v).
    (d) Technical Amendment.--Section 1927(d)(1) of such Act (42 U.S.C. 
1396r-8(d)(1)) is amended in the paragraph heading by inserting ``and 
mandatory'' after ``permissible''.
    (e) Effective Date.--
            (1) In general.--Except as provided in paragraph (2), the 
        amendments made by this section shall take effect as if 
        included in the enactment of the Deficit Reduction Act of 2005 
        (Public Law 109-171).
            (2) Exception.--The amendments made by subsection (b) shall 
        take effect on the date that is 180 days after the date of 
        enactment of this Act.

A:
Fair Medicaid Drug Payment Act of 2007 - Amends title XIX (Medicaid) of the Social Security Act to direct the Secretary of Health and Human Services to calculate the federal upper reimbursement limit as no less than 300% of the weighted average (based on utilization) of the most recent average manufacturer prices (AMPs) for pharmaceutically and therapeutically equivalent multiple source drug products available for purchase by retail community pharmacies on a nationwide basis. Directs the Secretary to implement a smoothing process for AMPs to ensure that federal upper reimbursement limits do not vary significantly from month to month as a result of rebates, discounts, and other pricing practices.

Requires a state plan to subject to prior authorization all covered outpatient drug products that are innovator multiple source drugs, if such drug products are more expensive than other biologically and therapeutically equivalent drug products available for purchase in that state by retail community pharmacies.

Revises requirements for monthly reports to the Secretary of price information by manufacturers subject to rebate agreements.
****